Morgan Stanley has released a research report stating that following PHARMARON's (03759) first-half 2026 earnings release, the firm has raised its 2026-2030 forecasts by 1-6%.
This adjustment reflects higher revenue assumptions, management's updated guidance, and improved working capital efficiency.
The investment bank has lifted its price target on the stock from HK$31 to HK$35.6, while reiterating an "Overweight" rating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.